Halozyme Therapeutics | HALO - Interest Expense On Debt

Stock Price
78.57
Daily Change
0.64 0.82%
Monthly
7.44%
Yearly
35.61%
Q1 Forecast
69.50

Halozyme Therapeutics reported $4.3M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Alnylam Pharmaceuticals USD 44.4M 4.15M Sep/2025
Amarin USD 3K 5K Dec/2024
Amgen USD 653M 32M Dec/2025
Baxter International USD 58M 14M Sep/2025
Cytokinetics USD 26.32M 2.06M Sep/2025
DBV Technologies USD 461K 323.71K Mar/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Halozyme Therapeutics USD 4.3M 98K Sep/2025
Ionis Pharmaceuticals USD 18M 1000K Sep/2025
MannKind USD 7.33M 1.14M Sep/2025
Pfizer USD 711M 59M Dec/2025
United Therapeutics USD 3M 4.3M Sep/2025